Home » Topics » Regulatory » Patents

Patents
RSS

Researchers at Janssen/Neurocrine Biosciences develop CRF antagonists

Oct. 27, 1997

ARS discloses new 5alpha-reductase inhibitors

Oct. 27, 1997

Factor Xa inhibitors from Zeneca for use as anticoagulants/antithrombotics

Oct. 27, 1997

Improved DNA topoisomerase poisons discovered at Rutgers

Oct. 24, 1997

Anti-H. pylori cephems claimed by Fujisawa

Oct. 24, 1997

Abbott develops inhibitors of LT biosynthesis

Oct. 24, 1997

Janssen discloses agents that promote gastrointestinal motility

Oct. 24, 1997

New antidiabetic agents from Boehringer Mannheim

Oct. 24, 1997

VEGF inhibitors described by Zeneca

Oct. 24, 1997

Novel angiotensin II antagonists for hypertension/CHF

Oct. 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 19, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 19, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...